AxoGen, Inc (AXGN)

Etorro trading 970x250
AxoGen, Inc (AXGN) Logo

About AxoGen, Inc

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida. Address: 13631 Progress Boulevard, Alachua, FL, United States, 32615

AxoGen, Inc News and around…

Latest news about AxoGen, Inc (AXGN) common stock and company :

AxoGen (NASDAQ:AXGN) investors are sitting on a loss of 59% if they invested three years ago
17 Oct, 2021 Yahoo! Finance

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...

Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
13 Oct, 2021 Yahoo! Finance

ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET. Investors interested in participatin

Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
22 Sep, 2021 FinancialContent

Industry leading nerve repair surgeons will share best practices and case studies during symposium session

XHE's Holdings Could Mean 16% Gain Potential
10 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $153.14 per unit.

Axogen RECON(SM) Clinical Study Completes Subject Follow-up
01 Sep, 2021 FinancialContent

RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft

Could The AxoGen, Inc. (NASDAQ:AXGN) Ownership Structure Tell Us Something Useful?
18 Aug, 2021 Yahoo! Finance

A look at the shareholders of AxoGen, Inc. ( NASDAQ:AXGN ) can tell us which group is most powerful. Generally...

AxoGen, inc (AXGN) Q2 2021 Earnings Call Transcript
05 Aug, 2021 FinancialContent

AXGN earnings call for the period ending June 30, 2021.

AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
04 Aug, 2021 Yahoo! Finance

AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and 3.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Axogen, Inc. Reports 2021 Second Quarter Financial Results
04 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
01 Aug, 2021 FinancialContent

Biotech stocks showed a lack of direction in the week endingJuly 30 amid earnings releases from big pharma companies. Most ...

AxoGen (AXGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
28 Jul, 2021 Yahoo! Finance

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
22 Jul, 2021 FinancialContent
Axogen, Inc. Appoints John H. Johnson to Board of Directors
19 Jul, 2021 FinancialContent

Global leader brings 30+ years of biopharma experience to Axogen, Inc. Board of Directors

Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
14 Jul, 2021 FinancialContent
Health Check: How Prudently Does AxoGen (NASDAQ:AXGN) Use Debt?
19 Jun, 2021 Yahoo! Finance

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Wednesday's ETF Movers: PBW, IHI
26 May, 2021 FinancialContent

In trading on Wednesday, the Invesco WilderHill Clean Energy ETF is outperforming other ETFs, up about 3.9% on the day. Components of that ETF showing particular strength include shares of Arcimoto, up about 18.5% and shares of Beam Global, up about 17.8% on the day.

Axogen To Stop Commercial Sales Of Avive Soft Tissue Membrane Pending Discussions With FDA
18 May, 2021 FinancialContent

Axogen Inc(NASDAQ: AXGN) has announced to suspend the market availability of Avive Soft Tissue Membrane (Avive) effective June ...

Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
18 May, 2021 FinancialContent
AxoGen (AXGN) Stock Jumps 12.5%: Will It Continue to Soar?
07 May, 2021 Yahoo! Finance

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

72 Biggest Movers From Yesterday
07 May, 2021 FinancialContent

Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, ...

Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
06 May, 2021 FinancialContent
AxoGen Inc (AXGN) Q1 2021 Earnings Call Transcript
06 May, 2021 FinancialContent

AXGN earnings call for the period ending March 31, 2021.

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
05 May, 2021 Yahoo! Finance

AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Recap: Axogen Q1 Earnings
05 May, 2021 FinancialContent

Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly ...

Axogen, Inc. Reports 2021 First Quarter Financial Results
05 May, 2021 FinancialContent
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
05 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For May 5, 2021
05 May, 2021 FinancialContent

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second ...

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
01 May, 2021 FinancialContent

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA ...

Peek Under The Hood: XHE Has 15% Upside
20 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Health Care Equipment ETF (XHE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $139.81 per unit.

AxoGen, Inc (AXGN) is a NASDAQ Common Stock listed in , ,

970x250